Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CBOE GLOBAL MARKETS

Real-time Estimate Cboe BZX  -  02:37:13 2023-06-08 pm EDT
135.01 USD   +31.57%
06/02Cboe Launches New Global Listing Offering for Companies and ETFs of the Purpose-Driven Innovation Economy
AQ
05/30CBOE GLOBAL MARKETS, INC. : Ex-dividend day for
FA
05/16CBOE GLOBAL MARKETS, INC. : SEC Filing 8K
CO
SummaryChartsNewsCalendarCompanyFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cboe Global Markets : ACETO Enters into Stalking Horse Agreement to Sell Rising Pharmaceuticals

03/08/2019 | 04:40am EDT
ACETO Enters into Stalking Horse Agreement to Sell Rising Pharmaceuticals

Charles Gross 3/8/2019 2:57:52 AM

ACETO Corporation (NASDAQ: ACET) announced that it has entered into a 'stalking-horse' asset purchase agreement with Shore Suven Pharma, Inc. to sell the assets of Rising Pharmaceuticals and Rising's subsidiaries for gross cash proceeds of $15 million, plus the assumption of operating liabilities and customer obligations related to the acquired business on a cash-free and debt-free basis.

Shore Suven Pharma, Inc. is a joint venture between Suven Life Sciences Limited, an India-based provider of contract research and manufacturing services for the global life sciences industry, and Shore Pharma Investments, LLC, a company founded by Vimal Kavuru to acquire generic drug assets. Mr. Kavuru is a member of Aceto's Board of Directors.

'We are very pleased to have completed a 'stalking horse' asset purchase agreement for Rising Pharmaceuticals. With its deep expertise in the generic drugs industry, Shore Suven Pharma ensures a seamless transition of Rising's portfolio, customer programs and manufacturing and drug development relationships,' said William C. Kennally III, Chief Executive Officer of Aceto. 'Strategically, this proposed transaction will help Rising balance its asset light business model through the opportunity to vertically integrate with a drug development lab and achieve greater control over its business going forward.'

'We are extremely pleased to have this opportunity to expand our global footprint. Leveraging Rising's product portfolio to become vertically integrated with our well-respected API and finished dose manufacturing capabilities will enable us to better serve U.S. customers,' said Mr. Venkat Jasti, CEO and Chairman of Suven Life Sciences.

'The opportunity to work with Rising's suppliers and employees to ensure continuity of product supply to customers in connection with this proposed integration will be our top priority. We have an experienced generic pharmaceutical management team ready to facilitate a smooth transition while maximizing the value of these assets. We look forward to working towards a successful closing,' said Mr. Kavuru, who will serve as CEO of Shore Suven Pharma.

The proposed sale will be conducted through a Court-supervised process under Section 363 of the Bankruptcy Code, subject to Court-approved bidding procedures, potential receipt of higher and better offers at auction; approval of the sale by the Court; and, the satisfaction of certain other conditions, including a mutual release of claims against certain of the buyer parties and their affiliates. As previously announced, Aceto has also entered into a 'stalking horse' agreement to sell its chemicals business through a Court-supervised process under Section 363 of the Bankruptcy Code. PJT Partners LP is acting as Aceto's financial advisor and investment banker to lead the sales processes under the bid procedures and Lowenstein Sandler LLP is serving as legal advisor. AP Services, an affiliate of AlixPartners LLP, is also serving as Chief Financial Officer and advisor to the Company.

Shore Suven Pharma, Inc. is represented by Reed Smith LLP. Citadel Management Consulting, a pharmaceutical-focused investment banking firm based in Hyderabad, India, also advised Shore Suven Pharma on this transaction.

To facilitate the sale of both Rising Pharmaceuticals and its chemicals business assets, Aceto and its U.S. subsidiaries filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of New Jersey (Newark) on February 19, 2019. The Company expects to complete the dispositions of its chemicals and Rising businesses before its fiscal year end on June 30, 2019.

Disclaimer

CBOE Holdings Inc. published this content on 08 March 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 08 March 2019 09:39:05 UTC


ę Publicnow 2019
All news about CBOE GLOBAL MARKETS
06/02Cboe Launches New Global Listing Offering for Companies and ETFs of the Purpose-Driven ..
AQ
05/30CBOE GLOBAL MARKETS, INC. : Ex-dividend day for
FA
05/16CBOE GLOBAL MARKETS, INC. : SEC Filing 8K
CO
05/16CBOE GLOBAL MARKETS, INC. : SEC Filing 4K
CO
05/11CBOE GLOBAL MARKETS, INC. : Shareholders meeting voting result..
CO
05/11CBOE GLOBAL MARKETS, INC. : Dividends
CO
05/05Cboe Global Markets : Earning documents
PU
05/05CBOE GLOBAL MARKETS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/05Cboe : Q1 Earnings Snapshot
AQ
05/05CBOE GLOBAL MARKETS, INC. : SEC Filing 8K
CO
More news
Analyst Recommendations on CBOE GLOBAL MARKETS
More recommendations
Chart CBOE GLOBAL MARKETS
Duration : Period :
Cboe Global Markets Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Edward Thomas Tilly Chairman & Chief Executive Officer
David Howson President & Executive Vice President
Brian N. Schell Chief Financial Officer, Treasurer & Executive VP
Tim Lipscomb Chief Technology Officer & Senior Vice President
Christopher A. Isaacson Chief Operating Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
CBOE GLOBAL MARKETS-16.13%12 893
INTERCONTINENTAL EXCHANGE, INC.5.59%60 645
LONDON STOCK EXCHANGE PLC22.51%60 040
HONG KONG EXCHANGES AND CLEARING LIMITED-8.54%49 767
DEUTSCHE BÖRSE AG0.99%32 062
NASDAQ, INC.-7.01%27 998
MarketScreener: Created by Investors for Investors!
100% Free Registration
fermer